Login
bluebird bio, Inc. NASDAQ: BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
| Name | bluebird bio, Inc. |
| Ticker | BLUE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
31.10
25.62 / 73.84 |
| Momentum | Sharp Down |
| Market cap | 2.1 B |
| 1Y Total Return |
-57.00%
Weak |
| 1Y Volatility |
81.02%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
Details
| Ticker | BLUE |
| Name | bluebird bio, Inc. |
| ISIN | US09609G1004 |
| CUSIP | 09609G100 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 2/26/21
| Close Price | 31.10 |
| 52W Low/High | 25.62 / 73.84 |
| Market cap | 2.1 B |
| 1Y Total Return |
-57.00%
Weak |
| 1Y Volatility |
81.02%
More Risk |
| Beta | 1.86 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -256.8% |
| Cash from Op. / Cur. Liabilities | -2.41 |
| Diluted Earnings / Share | -10.98 |
| ROE | - |
| ROIC | -46.8% |
| Price / Revenue | 8.2 |
| Price / Book | 1.4 |
| Price / CF | -4.3 |
| Current Ratio | 6.6 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.13 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
250
|
54
|
40
|
33
|
6
|
19
|
|
| Gross Profit |
245
|
51
|
39
|
31
|
6
|
19
|
|
| R&D |
613
|
540
|
421
|
238
|
183
|
119
|
|
| EBITDA |
-639
|
-733
|
-516
|
-279
|
-231
|
-132
|
|
| Operating Income |
-654
|
-738
|
-532
|
-287
|
-241
|
-137
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
66
|
55
|
53
|
46
|
37
|
36
|
|
| EPS exc. Extra |
-10.98
|
-13.00
|
-10.52
|
-7.02
|
-6.47
|
-4.20
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
1,945
|
1,892
|
2,352
|
1,406
|
918
|
1,018
|
|
| Cash, Eq & Invt ShortTerm |
1,230
|
1,180
|
1,695
|
729
|
601
|
707
|
|
| Total Current Assets |
1,293
|
1,220
|
1,725
|
759
|
609
|
713
|
|
| Total Non-Current Assets |
652
|
672
|
626
|
647
|
309
|
304
|
|
| Intangibles |
24
|
29
|
27
|
31
|
35
|
39
|
|
| Total Liabilities |
422
|
421
|
351
|
264
|
224
|
129
|
|
| Total Current Liabilities |
197
|
196
|
132
|
77
|
68
|
34
|
|
| Long Term Debt |
226
|
224
|
219
|
188
|
156
|
95
|
|
| Shareholder equity |
1,523
|
1,472
|
2,001
|
1,141
|
695
|
889
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-474
|
-535
|
-379
|
-254
|
-154
|
-81
|
|
| Depreciation |
19
|
17
|
16
|
12
|
9
|
7
|
|
| Cash from Investing |
-50
|
-97
|
-231
|
-477
|
-22
|
-323
|
|
| Capex |
33
|
72
|
62
|
56
|
18
|
6
|
|
| Cash from Financing |
547
|
21
|
1,324
|
728
|
3
|
732
|
|
| Stock Issued |
547
|
21
|
1,322
|
689
|
5
|
732
|
|
| Debt (LT) Issued |
0
|
0
|
-1
|
0
|
0
|
0
|
|
| Free Cash Flow |
-753
|
-886
|
-782
|
-467
|
-278
|
-306
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
6.6
|
6.2
|
13.1
|
9.9
|
9.0
|
21.2
|
|
| Financial Leverage D/E |
0.13
|
0.13
|
0.08
|
0.14
|
0.14
|
0.05
|
|
| Return on Capital Avg |
-46.8%
|
-56.2%
|
-45.1%
|
-34.4%
|
-40.8%
|
-36.2%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available